期刊
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT
卷 22, 期 -, 页码 1-10出版社
CELL PRESS
DOI: 10.1016/j.omtm.2021.04.017
关键词
-
资金
- National Institutes of Health, National Heart, Lung, and Blood Institute [P01 HL059407]
Gene therapy for hypercholesterolemia shows promising results in LDLR-deficient mice with significant reduction of serum LDL-C levels. The combination of codon and vector optimization enhanced transgene expression and sustained therapeutic effects in male DKO mice. The second-generation clinical candidate vector demonstrated potential for effective treatment in HoFH patients.
Gene therapy for hypercholesterolemia offers the potential to sustainably ameliorate disease for life with a single dose. In this study, we demonstrate the combinatorial effects of codon and vector optimization, which significantly improve the efficacy of an adeno-associated virus (AAV) vector in the low-density lipoprotein receptor (LDLR)-deficient mouse model (Ldlr(-/-), Apobec1(-/-) double knockout [DKO]). This study investigated vector efficacy following the combination of intervening sequence 2 (IVS2) of the human beta-globin gene and codon optimization with the previously developed gain-of-function, human LDLR triple-mutant variant (hLDLR-L318D/K809R/C818A) in the treatment of homozygous familial hypercholesterolemia (HoFH). Vector doses as low as 3 x 10(11) genome copies (GC)/kg achieved a robust reduction of serumlow-density lipoprotein cholesterol (LDL-C) by 98% in male LDLR-deficient mice. Less efficient LDL-C reduction was observed in female mice, which was attributable to lower gene transfer efficiency in liver. We also observed persistent and stable transgene expression for 120 days, with LDL-C levels being undetectable in male DKO mice treated with the second-generation vector. In conclusion, codon and vector optimization enhanced transgene expression and reduced serum LDL-C levels effectively at a lower dose in LDLR-deficient mice. The second-generation clinical candidate vector we have developed has the potential to achieve therapeutic effects in HoFH patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据